Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PerserisTM: A New and Long-Acting, Atypical Antipsychotic Drug-Delivery System.

Literature DB >> 31447532

Perseris^TM: A New and Long-Acting, Atypical Antipsychotic Drug-Delivery System.

Andrew Karas, Gary Burdge, Jose A Rey.

Abstract

Perseris: A new, long-acting, atypical antipsychotic drug-delivery system.

Entities: Disease

Year: 2019 PMID： 31447532 PMCID： PMC6679950

Source DB: PubMed Journal: P T ISSN： 1052-1372

26 in total

1. Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population.

Authors: Timothy L Boaz; Robert J Constantine; John Robst; Marion A Becker; Andrew M Howe
Journal: J Clin Psychiatry Date: 2010-10-19 Impact factor: 4.384

2. An examination of costs, charges, and payments for inpatient psychiatric treatment in community hospitals.

Authors: Michael Stensland; Peter R Watson; Kyle L Grazier
Journal: Psychiatr Serv Date: 2012-07 Impact factor: 3.084

3. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

Authors: Natalie C Edwards; Julie C Locklear; Marcia F T Rupnow; Ronald J Diamond
Journal: Pharmacoeconomics Date: 2005 Impact factor: 4.981

Review 4. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature.

Authors: Jonathan P Lacro; Laura B Dunn; Christian R Dolder; Susan G Leckband; Dilip V Jeste
Journal: J Clin Psychiatry Date: 2002-10 Impact factor: 4.384

5. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

Authors: Jari Tiihonen; Jari Haukka; Mark Taylor; Peter M Haddad; Maxine X Patel; Pasi Korhonen
Journal: Am J Psychiatry Date: 2011-03-01 Impact factor: 18.112

6. Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year.

Authors: W Wolfgang Fleischhacker; Jonathan Rabinowitz; Georg Kemmler; Mariëlle Eerdekens; Angelika Mehnert
Journal: Br J Psychiatry Date: 2005-08 Impact factor: 9.319

7. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone.

Authors: Henry A Nasrallah; Inge Duchesne; Angelika Mehnert; Carmela Janagap; Mariëlle Eerdekens
Journal: J Clin Psychiatry Date: 2004-04 Impact factor: 4.384

8. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain.

Authors: Anil K Malhotra; Christoph U Correll; Nabilah I Chowdhury; Daniel J Müller; Peter K Gregersen; Annette T Lee; Arun K Tiwari; John M Kane; W Wolfgang Fleischhacker; Rene S Kahn; Roel A Ophoff; Herbert Y Meltzer; Todd Lencz; James L Kennedy
Journal: Arch Gen Psychiatry Date: 2012-09

9. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic.

Authors: Mahesh N Samtani; An Vermeulen; Kim Stuyckens
Journal: Clin Pharmacokinet Date: 2009 Impact factor: 6.447